Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I...
During the October–December 2025 quarter, Thor Energy advanced its HY-Range natural hydrogen and helium project toward drill readiness, completed key non-dilutive asset monetisations, and reinforced its exposure to South Australian copper-gold assets...
Likewise Group CEO Tony Brewer explains how the company achieved 8.6% revenue growth in a down market — and why its infrastructure investments signal ambitions well beyond £250m...
Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I...
During the October–December 2025 quarter, Thor Energy advanced its HY-Range natural hydrogen and helium project toward drill readiness, completed key non-dilutive asset monetisations, and reinforced its exposure to South Australian copper-gold assets...
Likewise Group CEO Tony Brewer explains how the company achieved 8.6% revenue growth in a down market — and why its infrastructure investments signal ambitions well beyond £250m...